Breast Cancer Clinical Trials

**SUSPENDED** ALLIANCE A011104  Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (Feig)
UCI 15-83  Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (Tromberg)
UCI 10-39  Predicting Pathological Response within the First Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured with Diffuse Optical Spectroscopic Imaging (DOSI) (Tromberg)
UCI 11-15  Correlation of Clinical and MRI Findings with Prognosis of Breast Cancer Patients (Su)
UCI 11-21  Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (Su)
UCI 14-86  Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (Su)
UCI 14-85  Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System (Su)
UCI 16-23  Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (Anton-Culver)

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu
Breast Cancer Therapeutic Clinical Trials

**Breast Cancer**

**Adjuvant**

SWOG S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer (Mehta)

SWOG S1418 Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy (Mehta)

ALLIANCE A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (Mehta)

**Neo-Adjuvant**

UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

UCI 14-67 A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Mehta)

**Stage I-III**

HER2- High Risk

HER2+ High Risk

Hormone+ High Risk

SWOG S1418 Phase III Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Mehta)

**Multiple Disease Sites**

UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

For more details contact 1-877-UC-STUDY or ucsstudy@uci.edu

**opening soon** 1217
Breast Cancer Therapeutic Clinical Trials

**Advanced**

**Metastatic**

**Targeted therapy**

- **ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) (Bota)
- **SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)
- **NRG BR002** A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (Daroui)
- **UCI 16-74** A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)
- **NSABP FB-10** A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer (Parajuli)
- **UCI 17-79** Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (Parajuli)

**For more details contact 1-877-UC-STUDY or ucstudy@uci.edu**